William E Evans

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6861454/publications.pdf

Version: 2024-02-01

471 papers	55,163 citations	905 116 h-index	1345 223 g-index
487 all docs	487 docs citations	487 times ranked	31759 citing authors

#	Article	IF	Citations
1	Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy. Haematologica, 2022, 107, 371-380.	1.7	5
2	Comprehensive characterization of pharmacogenetic variants in TPMT and NUDT15 in children with acute lymphoblastic leukemia. Pharmacogenetics and Genomics, 2022, 32, 60-66.	0.7	7
3	Association of Genetic Ancestry With the Molecular Subtypes and Prognosis of Childhood Acute Lymphoblastic Leukemia. JAMA Oncology, 2022, 8, 354.	3.4	35
4	Association between CEP72 genotype and persistent neuropathy in survivors of childhood acute lymphoblastic leukemia. Leukemia, 2022, 36, 1160-1163.	3.3	4
5	Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation. Nature Genetics, 2022, 54, 170-179.	9.4	29
6	CASPorter: A Novel Inducible Human CASP1/NALP3/ASC Inflammasome Biosensor. Journal of Inflammation Research, 2022, Volume 15, 1183-1194.	1.6	0
7	Simultaneous monitoring of disease and microbe dynamics through plasma DNA sequencing in pediatric patients with acute lymphoblastic leukemia. Science Advances, 2022, 8, eabj1360.	4.7	2
8	Remembering Donald Pinkel, MD: Acute lymphoblastic leukaemia pioneer September 7, 1926 â€"March 9, 2022. Leukemia, 2022, 36, 1444-1445.	3.3	0
9	Molybdenum Cofactor Catabolism Unravels the Physiological Role of the Drug Metabolizing Enzyme Thiopurine Sâ€Methyltransferase. Clinical Pharmacology and Therapeutics, 2022, 112, 808-816.	2.3	5
10	Amino acid stress response genes promote L-asparaginase resistance in pediatric acute lymphoblastic leukemia. Blood Advances, 2022, 6, 3386-3397.	2.5	8
11	Genome-Wide Association Study of Susceptibility Loci for TCF3-PBX1 Acute Lymphoblastic Leukemia in Children. Journal of the National Cancer Institute, 2021, 113, 933-937.	3.0	9
12	Effects of NT5C2 Germline Variants on 6â€Mecaptopurine Metabolism in Children With Acute Lymphoblastic Leukemia. Clinical Pharmacology and Therapeutics, 2021, 109, 1538-1545.	2.3	5
13	Association ofGATA3Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia. Journal of the National Cancer Institute, 2021, 113, 408-417.	3.0	16
14	Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nature Cancer, 2021, 2, 284-299.	5.7	70
15	Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks. Leukemia, 2021, 35, 3078-3091.	3.3	15
16	Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity. Clinical Pharmacology and Therapeutics, 2021, 110, 794-802.	2.3	7
17	Improving the treatment of childhood acute lymphoblastic leukemia by optimizing the use of 70-year-old drugs. Haematologica, 2021, 106, 2794-2796.	1.7	2
18	Identification of small molecules that mitigate vincristineâ€induced neurotoxicity while sensitizing leukemia cells to vincristine. Clinical and Translational Science, 2021, 14, 1490-1504.	1.5	12

#	Article	IF	Citations
19	Individual prediction of nonadherence to oral mercaptopurine in children with acute lymphoblastic leukemia: Results from COG AALL03N1. Cancer, 2021, 127, 3832-3839.	2.0	8
20	Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia. Cancer Discovery, 2021, 11, 2846-2867.	7.7	83
21	Concordance between self-reported symptoms and clinically ascertained peripheral neuropathy among childhood cancer survivors: the St. Jude Lifetime Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, cebp.0644.2021.	1.1	3
22	Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia. Journal of Clinical Investigation, 2021, 131, .	3.9	20
23	Hypomethylation of NLRP3 gene promoter discriminates glucocorticoidâ€resistant from glucocorticoidâ€sensitive idiopathic nephrotic syndrome patients. Clinical and Translational Science, 2021, 14, 964-975.	1.5	13
24	New insights into methotrexate accumulation in leukemia cells in vivo. Molecular and Cellular Oncology, 2021, 8, 1865086.	0.3	3
25	The Impact of Genetic Ancestry on the Biology and Prognosis of Childhood Acute Lymphoblastic Leukemia. Blood, 2021, 138, 3476-3476.	0.6	0
26	Clofarabine-Based Chemotherapy for KMT2Ar Infantile Acute Lymphoblastic Leukemia. Blood, 2021, 138, 3406-3406.	0.6	1
27	Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2020, 67, e28040.	0.8	38
28	The Promise and the Reality of Genomics to Guide Precision Medicine in Pediatric Oncology: The Decade Ahead. Clinical Pharmacology and Therapeutics, 2020, 107, 176-180.	2.3	21
29	ARID5B Influences Antimetabolite Drug Sensitivity and Prognosis of Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2020, 26, 256-264.	3.2	25
30	miR-331-3p is involved in glucocorticoid resistance reversion by rapamycin through suppression of the MAPK signaling pathway. Cancer Chemotherapy and Pharmacology, 2020, 86, 361-374.	1.1	7
31	Fluoroquinolone prophylaxis does not increase risk of neuropathy in children with acute lymphoblastic leukemia. Cancer Medicine, 2020, 9, 6550-6555.	1.3	7
32	MO006INFLAMMASOME ACTIVATOR NLRP3 HYPOMETHYLATION IS ASSOCIATED WITH GLUCOCORTICOID RESISTANCE IN PATIENTS WITH IDIOPATHIC NEPHROTIC SYNDROME. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
33	Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. Nature Cancer, 2020, 1, 329-344.	5.7	44
34	Population Pharmacokinetics of Vincristine Related to Infusion Duration and Peripheral Neuropathy in Pediatric Oncology Patients. Cancers, 2020, 12, 1789.	1.7	18
35	ACCP: From zero to forty. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 8-9.	0.5	2
36	Mutational Landscape and Patterns of Clonal Evolution in Relapsed Pediatric Acute Lymphoblastic Leukemia. Blood Cancer Discovery, 2020, 1, 96-111.	2.6	93

#	Article	IF	Citations
37	Pharmacogenomics of intracellular methotrexate polyglutamates in patientsâ€™ leukemia cells in vivo. Journal of Clinical Investigation, 2020, 130, 6600-6615.	3.9	18
38	Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. Journal of Clinical Oncology, 2019, 37, 3377-3391.	0.8	169
39	Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge. Journal of Clinical Oncology, 2019, 37, 2051-2061.	0.8	61
40	Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models. PLoS ONE, 2019, 14, e0216328.	1.1	7
41	Genome-wide CRISPR screen reveals PSMA6 to be an essential gene in pancreatic cancer cells. BMC Cancer, 2019, 19, 253.	1.1	22
42	Genome-Wide Association Study of Susceptibility Loci for T-Cell Acute Lymphoblastic Leukemia in Children. Journal of the National Cancer Institute, 2019, 111, 1350-1357.	3.0	32
43	Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk. Nature Communications, 2019, 10, 5348.	5.8	58
44	Pharmacogenomics of Vincristineâ€Induced Peripheral Neuropathy: Progress Continues. Clinical Pharmacology and Therapeutics, 2019, 105, 315-317.	2.3	15
45	Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on <scp>TPMT</scp> and <scp>NUDT</scp>15 Genotypes: 2018 Update. Clinical Pharmacology and Therapeutics, 2019, 105, 1095-1105.	2.3	428
46	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nature Genetics, 2019, 51, 296-307.	9.4	384
47	Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics. Blood, 2019, 133, 724-729.	0.6	44
48	The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia. Blood, 2019, 134, 649-649.	0.6	5
49	Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. Cancer Cell, 2018, 33, 937-948.e8.	7.7	142
50	ASHP Foundation Pharmacy Forecast 2018: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems. American Journal of Health-System Pharmacy, 2018, 75, 23-54.	0.5	19
51	Pharmacogenomics and Hematologic Diseases. , 2018, , 79-91.		0
52	TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. Journal of Clinical Oncology, 2018, 36, 591-599.	0.8	121
53	Peripheral neuropathy in children and adolescents treated for cancer. The Lancet Child and Adolescent Health, 2018, 2, 744-754.	2.7	41
54	Multiplex assessment of protein variant abundance by massively parallel sequencing. Nature Genetics, 2018, 50, 874-882.	9.4	323

#	Article	IF	Citations
55	Alteration of RNA Splicing by Small-Molecule Inhibitors of the Interaction between NHP2L1 and U4. SLAS Discovery, 2018, 23, 164-173.	1.4	14
56	Pegaspargase Allergic Reactions Are Related to Anti-Pegaspargase Antibodies and to Intensity of Intrathecal Therapy. Blood, 2018, 132, 2697-2697.	0.6	2
57	Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. Blood, 2018, 132, 565-565.	0.6	14
58	The Effect of Asparaginase on Serum Triglycerides during Therapy for Acute Lymphoblastic Leukemia. Blood, 2018, 132, 2665-2665.	0.6	0
59	Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Childrenâ€™s Oncology Group study. Blood, 2017, 129, 1919-1926.	0.6	32
60	Differential effects of thiopurine methyltransferase (TPMT) and multidrug resistance-associated protein gene 4 (MRP4) on mercaptopurine toxicity. Cancer Chemotherapy and Pharmacology, 2017, 80, 287-293.	1.1	10
61	Genetics of pleiotropic effects of dexamethasone. Pharmacogenetics and Genomics, 2017, 27, 294-302.	0.7	17
62	Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry. Blood, 2017, 130, 1209-1212.	0.6	90
63	Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy. Leukemia, 2017, 31, 333-339.	3.3	140
64	An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristineâ€Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia. Clinical Pharmacology and Therapeutics, 2017, 101, 391-395.	2.3	51
65	A p53-regulated apoptotic gene signature predicts treatment response and outcome in pediatric acute lymphoblastic leukemia. Cancer Management and Research, 2017, Volume 9, 397-410.	0.9	4
66	Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Childrenâ€™s Oncology Group Study AALL03N1. Journal of Clinical Oncology, 2017, 35, 1730-1736.	0.8	26
67	Measuring mercaptopurine (6MP) adherence using red cell 6MP metabolite levels in children with acute lymphoblastic leukemia (ALL): A COG AALL03N1 study.. Journal of Clinical Oncology, 2017, 35, 10514-10514.	0.8	0
68	Vincristine pharmacogenomics. Pharmacogenetics and Genomics, 2016, 26, 51-52.	0.7	14
69	Msh2 deficiency leads to dysmyelination of the corpus callosum, impaired locomotion and altered sensory function in mice. Scientific Reports, 2016, 6, 30757.	1.6	3
70	Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2016, 34, 2133-2140.	0.8	88
71	Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nature Genetics, 2016, 48, 1481-1489.	9.4	231
72	Inflammasome-mediated glucocorticoid resistance: The receptor rheostat. Molecular and Cellular Oncology, 2016, 3, e1065947.	0.3	9

#	Article	IF	Citations
73	NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nature Genetics, 2016, 48, 367-373.	9.4	389
74	Comprehensive Functional Characterization of Germline ETV6 Variants Associated with Inherited Predisposition to Acute Lymphoblastic Leukemia in Children. Blood, 2016, 128, 1085-1085.	0.6	1
75	MicroRNAs Form Triplexes with Double Stranded DNA at Sequence-Specific Binding Sites; a Eukaryotic Mechanism via which microRNAs Could Directly Alter Gene Expression. PLoS Computational Biology, 2016, 12, e1004744.	1.5	62
76	Asparaginase May Affect Mercaptopurine Tolerability in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia. Blood, 2016, 128, 179-179.	0.6	0
77	BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures. Haematologica, 2015, 100, e354-e357.	1.7	76
78	Germline exome variation in children with acute lymphoblastic leukemia (ALL): Preliminary Findings. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S177.	0.2	0
79	Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels. Blood, 2015, 126, 2896-2899.	0.6	76
80	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood, 2015, 125, 680-686.	0.6	110
81	Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. Blood, 2015, 126, 1770-1776.	0.6	102
82	Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia. JAMA Oncology, 2015, 1, 287.	3.4	114
83	Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. Blood, 2015, 126, 69-75.	0.6	64
84	Effect of Premedications in a Murine Model of Asparaginase Hypersensitivity. Journal of Pharmacology and Experimental Therapeutics, 2015, 352, 541-551.	1.3	16
85	The Genomic Landscape of Childhood and Adolescent Melanoma. Journal of Investigative Dermatology, 2015, 135, 816-823.	0.3	148
86	Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children. Nature Communications, 2015, 6, 7553.	5.8	72
87	Association of an Inherited Genetic Variant With Vincristine-Related Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2015, 313, 815.	3.8	234
88	Inherited NUDT15 Variant Is a Genetic Determinant of Mercaptopurine Intolerance in Children With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2015, 33, 1235-1242.	0.8	369
89	NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nature Genetics, 2015, 47, 607-614.	9.4	126
90	Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncology, The, 2015, 16, 465-474.	5.1	177

#	Article	IF	Citations
91	Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. Lancet Oncology, The, 2015, 16, 1659-1666.	5.1	161
92	Pharmacogenomics in the clinic. Nature, 2015, 526, 343-350.	13.7	642
93	Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. Journal of Clinical Oncology, 2015, 33, 2938-2948.	0.8	747
94	Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers. Annual Review of Pharmacology and Toxicology, 2015, 55, 89-106.	4.2	442
95	Genome-Wide Association Study Identifies PNPLA3 I148M Variant Associated with Elevated Transaminase Levels after Induction Therapy in Pediatric ALL Patients. Blood, 2015, 126, 3714-3714.	0.6	2
96	Expression of an Oncogenic ERG isoform Characterizes a Distinct Subtype of B-Progenitor Acute Lymphoblastic Leukemia. Blood, 2015, 126, 693-693.	0.6	1
97	6-Mercaptopurine (6MP) Intake during Maintenance for Childhood Acute Lymphoblastic Leukemia (ALL) - a Comparison of Self-Report and Electronic Monitoring: A Report from the Children's Oncology Group (COG) Study AALL03N1. Blood, 2015, 126, 82-82.	0.6	3
98	Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia. PLoS ONE, 2015, 10, e0135134.	1.1	13
99	High Incidence of Induction Failure and Poor Outcome in Patients with Gamma Delta T Cell Acute Lymphoblastic Leukemia. Blood, 2015, 126, 1421-1421.	0.6	2
100	Body Mass Index Is Not Associated with Early Treatment Response or Clinical Outcome in Children with Acute Lymphoblastic Leukemia. Blood, 2015, 126, 1299-1299.	0.6	0
101	Genomic Landscape of Relapsed Acute Lymphoblastic Leukemia. Blood, 2015, 126, 692-692.	0.6	3
102	Germline Genetic Variation in ETV6 and Predisposition to Childhood Acute Lymphoblastic Leukemia. Blood, 2015, 126, 695-695.	0.6	2
103	Development and use of active clinical decision support for preemptive pharmacogenomics. Journal of the American Medical Informatics Association: JAMIA, 2014, 21, e93-e99.	2.2	186
104	Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine model. Pharmacogenetics and Genomics, 2014, 24, 263-271.	0.7	9
105	Loss of TBL1XR1 Disrupts Glucocorticoid Receptor Recruitment to Chromatin and Results in Glucocorticoid Resistance in a B-Lymphoblastic Leukemia Model. Journal of Biological Chemistry, 2014, 289, 20502-20515.	1.6	52
106	Methotrexate-Induced Neurotoxicity and Leukoencephalopathy in Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2014, 32, 949-959.	0.8	275
107	PG4KDS: A model for the clinical implementation of preâ€emptive pharmacogenetics. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2014, 166, 45-55.	0.7	221
108	Outcomes of Children With BCR-ABL1â€"Like Acute Lymphoblastic Leukemia Treated With Risk-Directed Therapy Based on the Levels of Minimal Residual Disease. Journal of Clinical Oncology, 2014, 32, 3012-3020.	0.8	223

#	Article	IF	Citations
109	Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. Pharmacogenomics, 2014, 15, 1065-1078.	0.6	59
110	Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2014, 371, 1005-1015.	13.9	1,161
111	6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study. Blood, 2014, 124, 2345-2353.	0.6	164
112	HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. Blood, 2014, 124, 1266-1276.	0.6	84
113	Glutamate Receptor Polymorphisms Contribute to Glucocorticoid-Associated Osteonecrosis. Blood, 2014, 124, 367-367.	0.6	1
114	ARID5B Regulates Leukemia Sensitivity to Antimetabolites in Children with Acute Lymphoblastic Leukemia Via Effects on Cell Cycle Progression. Blood, 2014, 124, 791-791.	0.6	28
115	Factors associated with nonadherence to oral 6-mercaptopurine (6MP) in children with acute lymphoblastic leukemia (ALL): A report from Childrenâ€™s Oncology Group (COG) study AALL03N1.. Journal of Clinical Oncology, 2014, 32, 10013-10013.	0.8	2
116	Abstract CT409: Dexamethasone (dex) and asparaginase increase triglycerides during acute lymphoblastic leukemia (ALL) therapy in children. , 2014, , .		0
117	A Murine Model of Asparaginase Allergy. Blood, 2014, 124, 2295-2295.	0.6	0
118	Genetic Variation in NFATC2 Is Associated with a Higher Risk of Asparaginase Allergy. Blood, 2014, 124, 63-63.	0.6	6
119	Tolerability of 6-Mercaptopurine (6MP) in Patients with Thiopurine Methyltransferase (TPMT) Heterozygosity in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 3722-3722.	0.6	0
120	A Genome-Wide Association Study of Susceptibility to Acute Lymphoblastic Leukemia in Adolescents and Young Adults. Blood, 2014, 124, 132-132.	0.6	1
121	Impact of 6 Mercaptopurine (6MP) Pill-Taking Habits on Adherence, Thioguanine Nucleotide (TGN) Levels and Relapse Risk in Children with Acute Lymphoblastic Leukemia (ALL): Results from a Childrenâ€™s Oncology Group (COG) Study (AALL03N1). Blood, 2014, 124, 369-369.	0.6	0
122	Antileukemic Efficacy of Continuous Vs Discontinuous Dexamethasone in Murine Xenografts of Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3701-3701.	0.6	1
123	Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. Cancer Chemotherapy and Pharmacology, 2013, 72, 369-378.	1.1	36
124	A 50-Year Journey to Cure Childhood Acute Lymphoblastic Leukemia. Seminars in Hematology, 2013, 50, 185-196.	1.8	264
125	A Health-Care System Perspective on Implementing Genomic Medicine: Pediatric Acute Lymphoblastic Leukemia as a Paradigm. Clinical Pharmacology and Therapeutics, 2013, 94, 224-229.	2.3	20
126	Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nature Genetics, 2013, 45, 290-294.	9.4	264

#	Article	IF	Citations
127	The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real-World Implementation. Clinical Pharmacology and Therapeutics, 2013, 94, 207-210.	2.3	164
128	Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nature Genetics, 2013, 45, 1494-1498.	9.4	264
129	Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update. Clinical Pharmacology and Therapeutics, 2013, 93, 324-325.	2.3	304
130	Novel Susceptibility Variants at 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethnically Diverse Populations. Journal of the National Cancer Institute, 2013, 105, 733-742.	3.0	208
131	Mathematical modeling of folate metabolism. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2013, 5, 603-613.	6.6	6
132	Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood, 2013, 121, 898-904.	0.6	174
133	Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood, 2013, 122, 2622-2629.	0.6	248
134	Nomenclature for alleles of the thiopurine methyltransferase gene. Pharmacogenetics and Genomics, 2013, 23, 242-248.	0.7	104
135	The synergism of MCL1 and glycolysis on pediatric acute lymphoblastic leukemia cell survival and prednisolone resistance. Haematologica, 2013, 98, 1905-1911.	1.7	23
136	High Intra-Individual Variability In Systemic Exposure To 6 Mercaptopurine (6MP) In Children With Acute Lymphoblastic Leukemia (ALL) Contributes To ALL Relapse: Results From a Childrenâ€™s Oncology Group (COG) Study (AALL03N1). Blood, 2013, 122, 59-59.	0.6	5
137	HLA-DRB1*07:01 Is Associated With Asparaginase Allergies In Children With Acute Lymphoblastic Leukemia. Blood, 2013, 122, 60-60.	0.6	1
138	Genome-Wide Association Analyses Identify Susceptibility Loci For Vincristine-Induced Peripheral Neuropathy In Children With Acute Lymphoblastic Leukemia. Blood, 2013, 122, 618-618.	0.6	6
139	BCR-ABL1-Like Cases In Pediatric Acute Lymphoblastic Leukemia: A Comparison Between COG/St. Jude and Dutch DCOG Signatures. Blood, 2013, 122, 2633-2633.	0.6	1
140	PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Human Molecular Genetics, 2012, 21, 4793-4804.	1.4	56
141	Treatment Outcomes in Black and White Children With Cancer: Results From the SEER Database and St Jude Children's Research Hospital, 1992 Through 2007. Journal of Clinical Oncology, 2012, 30, 2005-2012.	0.8	104
142	ARID5B Genetic Polymorphisms Contribute to Racial Disparities in the Incidence and Treatment Outcome of Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2012, 30, 751-757.	0.8	165
143	ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy. Leukemia, 2012, 26, 265-270.	3.3	112
144	Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Research, 2012, 22, 1-8.	2.4	232

#	Article	IF	Citations
145	2012 Remington Lecture: Culture trumps strategy: We must encourage the next generation of pharmacists to keep looking over the horizon and not be limited by what they can see today. Journal of the American Pharmacists Association: JAPhA, 2012, 52, 450-453.	0.7	1
146	A Clinician-Driven Automated System for Integration of Pharmacogenetic Interpretations Into an Electronic Medical Record. Clinical Pharmacology and Therapeutics, 2012, 92, 563-566.	2.3	94
147	Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood, 2012, 119, 1658-1664.	0.6	77
148	Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood, 2012, 120, 4197-4204.	0.6	103
149	Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia. Cancer Cell, 2012, 22, 153-166.	7.7	621
150	Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia, 2012, 26, 2303-2309.	3.3	93
151	The Pediatric Cancer Genome Project. Nature Genetics, 2012, 44, 619-622.	9.4	315
152	Pharmacogenomics and Individualized Medicine: Translating Science Into Practice. Clinical Pharmacology and Therapeutics, 2012, 92, 467-75.	2.3	183
153	The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature, 2012, 481, 157-163.	13.7	1,430
154	Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?. Blood, 2012, 120, 1165-1174.	0.6	439
155	A Genome-Wide Analysis of Variants Influencing Methotrexate Clearance Replicates SLCO1B1.. Blood, 2012, 120, 2466-2466.	0.6	5
156	Prednisolone Resistance in Pediatric Acute Lymphoblastic Leukemia Can Be Synergistically Overcome by Inhibition of Anti-Apoptotic MCL1 and Glycolysis. Blood, 2012, 120, 3528-3528.	0.6	1
157	Genome-Wide Association Study Identifies Germline Polymorphisms Associated with Relapse of Childhood Acute Lymphoblastic Leukemia. Blood, 2012, 120, 878-878.	0.6	0
158	PDE4B Modulates Glucocorticoid Sensitivity in Childhood Acute Lymphoblastic Leukemia. Blood, 2012, 120, 530-530.	0.6	3
159	The Potential of Aurora Kinases A and B As Therapeutic Targets in Pediatric Acute Leukemia. Blood, 2012, 120, 1465-1465.	0.6	0
160	Genome-Wide Association Study Identifies a Novel Susceptibility Locus At 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethinically Diverse Populations. Blood, 2012, 120, 877-877.	0.6	2
161	Host Thiopurine Methyltransferase Status Affects Mercaptopurine Antileukemic Effectiveness. Blood, 2012, 120, 3560-3560.	0.6	0
162	Leukemia Cells with a BCR-ABL1-Like signature and/or IKZF1 deletions, but Not High CRLF2 Expression, Are Predictive of an Unfavorable Prognosis in Childhood B Cell Precursor Acute Lymphoblastic Leukemia. Blood, 2012, 120, 880-880.	0.6	11

#	Article	IF	Citations
163	Shortening Infusion Time for High-Dose Methotrexate Alters Antileukemic Effects: A Randomized Prospective Clinical Trial. Journal of Clinical Oncology, 2011, 29, 1771-1778.	0.8	45
164	Cancer Pharmacogenomics. Clinical Pharmacology and Therapeutics, 2011, 90, 461-466.	2.3	34
165	Integrated analysis of pharmacologic, clinical and SNP microarray data using Projection Onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing. International Journal of Data Mining and Bioinformatics, 2011, 5, 143.	0.1	11
166	PharmGKB summary. Pharmacogenetics and Genomics, 2011, 21, 679-686.	0.7	120
167	Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood, 2011, 117, 2340-2347.	0.6	219
168	Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nature Genetics, 2011, 43, 237-241.	9.4	239
169	Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing. Clinical Pharmacology and Therapeutics, 2011, 89, 387-391.	2.3	504
170	A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity. Leukemia, 2011, 25, 66-74.	3.3	47
171	Improved Prognosis for Older Adolescents With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2011, 29, 386-391.	0.8	122
172	Reply to B.A. Kamen et al. Journal of Clinical Oncology, 2011, 29, 3494-3495.	0.8	0
173	Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nature Medicine, 2011, 17, 1298-1303.	15.2	133
174	SLCO1B1 Variation and Methotrexate Disposition in Children with Acute Lymphoblastic Leukemia: The Importance of Rare Variants in Pharmacogenetics. Blood, 2011, 118, 571-571.	0.6	0
175	Systemic Exposure to Dexamethasone and Asparaginase Affects Risk of Relapse in Children with Acute Lymphoblastic Leukemia. Blood, 2011, 118, 2550-2550.	0.6	0
176	Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project. Blood, 2011, 118, 68-68.	0.6	0
177	Aurora Kinases in Childhood Acute Leukemia: The Promise of Aurora Kinase B As Drugable Target. Blood, 2011, 118, 1476-1476.	0.6	0
178	Pharmacogenomics in pediatric leukemia. Current Opinion in Pediatrics, 2010, 22, 703-710.	1.0	28
179	Thiopurine pathway. Pharmacogenetics and Genomics, 2010, 20, 573-574.	0.7	89
180	Epigenetic Regulation of Human Î³-Glutamyl Hydrolase Activity in Acute Lymphoblastic Leukemia Cells. American Journal of Human Genetics, 2010, 87, 161.	2.6	8

#	Article	IF	Citations
181	Genetic Variations in GRIA1 on Chromosome 5q33 Related to Asparaginase Hypersensitivity. Clinical Pharmacology and Therapeutics, 2010, 88, 191-196.	2.3	69
182	Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia, 2010, 24, 371-382.	3.3	248
183	ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence. Leukemia, 2010, 24, 894-896.	3.3	82
184	MicroRNAs MiR-520d And Let-7d Are Dysregulated In An Animal Model Of Pulmonary Arterial Hypertension: Detection By Endoarterial Biopsy. , 2010, , .		0
185	Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status. Expert Opinion on Drug Safety, 2010, 9, 23-37.	1.0	52
186	Modeling Mechanisms of In Vivo Variability in Methotrexate Accumulation and Folate Pathway Inhibition in Acute Lymphoblastic Leukemia Cells. PLoS Computational Biology, 2010, 6, e1001019.	1.5	46
187	Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncology, The, 2010, 11, 507-509.	5.1	97
188	Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Determinants of Osteonecrosis In Children with Acute Lymphoblastic Leukemia.. Blood, 2010, 116, 1033-1033.	0.6	1
189	VPREB1 Deletions Occur Independent of Lambda-Light Chain Rearrangement and Predict Worse Outcome In Pediatric Acute Lymphoblastic Leukemia (ALL). Blood, 2010, 116, 273-273.	0.6	4
190	ARID5B Genetic Polymorphisms Contribute to Racial Disparities In Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. Blood, 2010, 116, 8-8.	0.6	1
191	Improved Prognosis for Older Adolescents with Acute Lymphoblastic Leukemia. Blood, 2010, 116, 498-498.	0.6	0
192	Excellent Outcome for ETV6/RUNX1-Positive Childhood Acute Lymphoblastic Leukemia (ALL) with Contemporary Therapy. Blood, 2010, 116, 495-495.	0.6	1
193	Integrated Analysis of Pharmacokinetic, Clinical, and SNP Microarray Data Using Projection onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing. , 2009, , .		1
194	Genome-wide Interrogation of Germline Genetic Variation Associated With Treatment Response in Childhood Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2009, 301, 393.	3.8	193
195	Germline Genetic Variation in an Organic Anion Transporter Polypeptide Associated With Methotrexate Pharmacokinetics and Clinical Effects. Journal of Clinical Oncology, 2009, 27, 5972-5978.	0.8	305
196	Pharm.D.-Only Investigators Are Critical to the Profession: Let's Preserve the Fellowship as an Equally Important Way to Prepare Future Clinical Pharmaceutical Scientists: Or the Case Against the â€œAll-Ph.D.â€• Pharmacotherapy, 2009, 29, 129-133.	1.2	11
197	TPMT genetic variations in populations of the Russian Federation. Pediatric Blood and Cancer, 2009, 52, 203-208.	0.8	26
198	Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Leukemia, 2009, 23, 1406-1409.	3.3	128

#	Article	IF	Citations
199	Genetic Polymorphism of Inosine Triphosphate Pyrophosphatase Is a Determinant of Mercaptopurine Metabolism and Toxicity During Treatment for Acute Lymphoblastic Leukemia. Clinical Pharmacology and Therapeutics, 2009, 85, 164-172.	2.3	196
200	Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nature Genetics, 2009, 41, 1001-1005.	9.4	459
201	Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation. New England Journal of Medicine, 2009, 360, 2730-2741.	13.9	1,059
202	Pharmacogenetics in Acute Lymphoblastic Leukemia. Seminars in Hematology, 2009, 46, 39-51.	1.8	55
203	A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncology, The, 2009, 10, 125-134.	5.1	826
204	High-dose Methotrexate: The Rationaleâ€¦. Journal of Pediatric Hematology/Oncology, 2009, 31, 224-225.	0.3	3
205	Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood, 2009, 113, 2014-2021.	0.6	189
206	Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Blood, 2009, 113, 4512-4520.	0.6	52
207	Chemotherapy in the Pediatric Patient. , 2009, , 173-207.		2
208	Pharmacogenomics of childhood acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology, 2009, 27, s3-s3.	0.8	0
209	Genetic Variations in GRIA1 On Chromosome 5q33 Related to Asparaginase Hypersensitivity in Childhood Acute Lymphoblastic Leukemia (ALL).. Blood, 2009, 114, 112-112.	0.6	0
210	The SWI/SNF Chromatin-Remodeling Complex and Glucocorticoid Resistance in Acute Lymphoblastic Leukemia. Journal of the National Cancer Institute, 2008, 100, 1792-1803.	3.0	61
211	Are children with lesser-risk B-lineage acute lymphoblastic leukemia curable with antimetabolite therapy?. Nature Clinical Practice Oncology, 2008, 5, 130-131.	4.3	4
212	Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity. Cancer Research, 2008, 68, 4983-4989.	0.4	124
213	In Vivo Response to Methotrexate Forecasts Outcome of Acute Lymphoblastic Leukemia and Has a Distinct Gene Expression Profile. PLoS Medicine, 2008, 5, e83.	3.9	75
214	Continue to study childhood ALL. Blood, 2008, 111, 468-469.	0.6	1
215	Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood, 2008, 112, 4178-4183.	0.6	179
216	Concordant Gene Expression in Leukemia Cells and Normal Leukocytes Is Associated with Germline cis-SNPs. PLoS ONE, 2008, 3, e2144.	1.1	8

#	Article	IF	Citations
217	Modulation of the Glycolysis Pathway Reverses Prednisolone Resistance in Pediatric Acute Lymphoblastic Leukemia Cells. Blood, 2008, 112, 17-17.	0.6	3
218	Genetically Defined Racial Differences Underlie Risk of Relapse in Childhood Acute Lymphoblastic Leukemia. Blood, 2008, 112, 14-14.	0.6	1
219	A Whole Genome Analysis Identifies SLCO1B1 as a Determinant of Methotrexate Pharmacokinetics and Adverse Effects. Blood, 2008, 112, 214-214.	0.6	8
220	Differential Effects of Targeted Disruption of Thiopurine Methyltransferase on Mercaptopurine and Thioguanine Pharmacodynamics. Cancer Research, 2007, 67, 4965-4972.	0.4	39
221	Cumulative Incidence of Secondary Neoplasms as a First Event After Childhood Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2007, 297, 1207.	3.8	261
222	Expression of SMARCB1 modulates steroid sensitivity in human lymphoblastoid cells: identification of a promoter snp that alters PARP1 binding and SMARCB1 expression. Human Molecular Genetics, 2007, 16, 2261-2271.	1.4	38
223	Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood, 2007, 109, 4151-4157.	0.6	190
224	Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature, 2007, 446, 758-764.	13.7	1,602
225	John H. Rodman, Pharm.D., FCCP January 6, 1946â€"April 29, 2006. Pharmacotherapy, 2007, 27, 1-2.	1.2	0
226	Inosine-Triphosphate-Pyrophosphatase Genotype Is a Determinant of Severe Fever with Neutropenia Following Treatment of Acute Lymphoblastic Leukemia with Combination Chemotherapy That Includes Mercaptopurine Adjusted for Thiopurine-S-Methyltransferase Genotype.. Blood, 2007, 110, 2827-2827.	0.6	0
227	Creating an infrastructure for pediatric oncology drug development. Clinical Advances in Hematology and Oncology, 2007, 5, 198-200.	0.3	0
228	PHARMACOGENOMICS OF ACUTE LEUKEMIA. Annual Review of Pharmacology and Toxicology, 2006, 46, 317-353.	4.2	37
229	Is mega dose of methotrexate beneficial to patients with acute lymphoblastic leukemia?. Leukemia and Lymphoma, 2006, 47, 2431-2432.	0.6	10
230	Epigenetic Regulation of Human Î³-Glutamyl Hydrolase Activity in Acute Lymphoblastic Leukemia Cells. American Journal of Human Genetics, 2006, 79, 264-274.	2.6	32
231	Treatment of Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2006, 354, 166-178.	13.9	1,740
232	The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood, 2006, 107, 769-776.	0.6	126
233	Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood, 2006, 107, 843-844.	0.6	127
234	Expression of the outcome predictor in acute leukemia 1 (OPAL1) gene is not an independent prognostic factor in patients treated according to COALL or St Jude protocols. Blood, 2006, 108, 1984-1990.	0.6	20

#	Article	IF	Citations
235	Pharmacogenomics of acute lymphoblastic leukemia. Current Opinion in Hematology, 2006, 13, 260-265.	1.2	38
236	Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nature Reviews Cancer, 2006, 6, 117-129.	12.8	205
237	Rapid genotyping of common deficient thiopurine S-methyltransferase alleles using the DNA-microchip technique. European Journal of Human Genetics, 2006, 14, 991-998.	1.4	29
238	Pharmacogenomics and Individualized Drug Therapy. Annual Review of Medicine, 2006, 57, 119-137.	5.0	576
239	Genes Regulating B-Cell Development and Differentiation Are Mutated in 40% of Pediatric Acute Lymphoblastic Leukemia.. Blood, 2006, 108, 217-217.	0.6	1
240	Pharmacokinetic, pharmacodynamic, and pharmacogenetic considerations. , 2006, , 391-413.		1
241	Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood, 2005, 105, 4223-4225.	0.6	70
242	Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood, 2005, 106, 1778-1785.	0.6	53
243	Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nature Genetics, 2005, 37, 878-882.	9.4	72
244	Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell, 2005, 7, 375-386.	7.7	150
245	Lymphoid gene expression as a predictor of risk of secondary brain tumors. Genes Chromosomes and Cancer, 2005, 42, 107-116.	1.5	30
246	Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer, 2005, 103, 368-376.	2.0	79
247	Risk of Adverse Events After Completion of Therapy for Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2005, 23, 7936-7941.	0.8	70
248	Global gene expression as a function of germline genetic variation. Human Molecular Genetics, 2005, 14, 1621-1629.	1.4	15
249	TELAML1-Positive ALL: A Discordant Genotype. Cell Cycle, 2005, 4, 997-998.	1.3	4
250	Cancer Pharmacogenomics May Require Both Qualitative and Quantitative Approaches. Cell Cycle, 2005, 4, 1506-1509.	1.3	11
251	Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood, 2005, 105, 4752-4758.	0.6	205
252	Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. Journal of Clinical Investigation, 2005, 115, 110-117.	3.9	129

#	Article	IF	Citations
253	A Journey from Pediatric Pharmacokinetics to Pharmacogenomics. Journal of Pediatric Pharmacology and Therapeutics, 2005, 10, 8-13.	0.3	4
254	Gene expression microarrays as a prognostic test. Clinical Advances in Hematology and Oncology, 2005, 3, 902-4.	0.3	1
255	A Novel CRM1-mediated Nuclear Export Signal Governs Nuclear Accumulation of Glyceraldehyde-3-phosphate Dehydrogenase following Genotoxic Stress. Journal of Biological Chemistry, 2004, 279, 5984-5992.	1.6	77
256	Gene expression as a drug discovery tool. Nature Genetics, 2004, 36, 214-215.	9.4	30
257	Moving towards individualized medicine with pharmacogenomics. Nature, 2004, 429, 464-468.	13.7	702
258	Statement by members of the Ponte di Legno Group on the right of children to have full access to essential treatment for acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2004, 43, 103-104.	0.8	14
259	Gene-Expression Patterns in Drug-Resistant Acute Lymphoblastic Leukemia Cells and Response to Treatment. New England Journal of Medicine, 2004, 351, 533-542.	13.9	565
260	Pharmacogenomics in cancer therapy: is host genome variability important?. Trends in Pharmacological Sciences, 2004, 25, 457-464.	4.0	33
261	Closing the gap between science and clinical practice. Pharmacogenetics and Genomics, 2004, 14, 395-396.	5.7	8
262	A substrate specific functional polymorphism of human Î³-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells. Pharmacogenetics and Genomics, 2004, 14, 557-567.	5.7	83
263	Pharmacogenetics of Thiopurine S-Methyltransferase and Thiopurine Therapy. Therapeutic Drug Monitoring, 2004, 26, 186-191.	1.0	183
264	Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis. Blood, 2004, 104, 1435-1441.	0.6	38
265	Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood, 2004, 104, 2690-2696.	0.6	412
266	Identification of Gene Expression Profiles in Acute Lymphoblastic Leukemia Cells That Discriminate Intracellular Thioguanine Nucleotide Accumulation in ALL Cells after In Vivo Treatment with Mercaptopurine.. Blood, 2004, 104, 453-453.	0.6	5
267	Genetic Polymorphisms in the Promoter Region of the beta-2 Adrenergic Receptor Are Associated with the Early Response of Acute Lymphoblastic Leukemia to Chemotherapy.. Blood, 2004, 104, 1959-1959.	0.6	0
268	Global Gene Expression in Leukemic Blasts as a Function of Germline Genetic Variation.. Blood, 2004, 104, 144-144.	0.6	1
269	Genetic Polymorphisms and the Toxicity of Antileukemic Agents in Children with Acute Lymphoblastic Leukemia.. Blood, 2004, 104, 1964-1964.	0.6	0
270	Expression arrays illuminate a way forward for mantle cell lymphoma. Cancer Cell, 2003, 3, 100-102.	7.7	4

#	Article	IF	Citations
271	Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia. Clinical Pharmacology and Therapeutics, 2003, 73, 506-516.	2.3	14
272	Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia, 2003, 17, 700-706.	3.3	216
273	Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene, 2003, 22, 7403-7413.	2.6	128
274	Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nature Genetics, 2003, 34, 85-90.	9.4	239
275	Pharmacogenomics â€" Drug Disposition, Drug Targets, and Side Effects. New England Journal of Medicine, 2003, 348, 538-549.	13.9	1,609
276	Structure and Dynamics of Thioguanine-modified Duplex DNA. Journal of Biological Chemistry, 2003, 278, 1005-1011.	1.6	89
277	Pharmacogenomics: marshalling the human genome to individualise drug therapy. Gut, 2003, 52, 10ii-18.	6.1	33
278	Extended Follow-up of Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2003, 349, 640-649.	13.9	415
279	Msh2 Deficiency Attenuates But Does Not Abolish Thiopurine Hematopoietic Toxicity inMsh2-/-Mice. Molecular Pharmacology, 2003, 64, 456-465.	1.0	11
280	Results of Therapy for Acute Lymphoblastic Leukemia in Black and White Children. JAMA - Journal of the American Medical Association, 2003, 290, 2001.	3.8	155
281	Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood, 2003, 101, 3862-3867.	0.6	145
282	A nuclear protein complex containing high mobility group proteins B1 and B2, heat shock cognate protein 70, ERp60, and glyceraldehyde-3-phosphate dehydrogenase is involved in the cytotoxic response to DNA modified by incorporation of anticancer nucleoside analogues. Cancer Research, 2003, 63, 100-6.	0.4	91
283	Outcomes of Growth Hormone Replacement Therapy in Survivors of Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2002, 20, 2959-2964.	0.8	90
284	From the Editors: progress and the way forward. Pharmacogenetics and Genomics, 2002, 12, 273-274.	5.7	0
285	Thiopurine S-methyltransferase: a genetic polymorphism that affects a small number of drugs in a big way. Pharmacogenetics and Genomics, 2002, 12, 421-423.	5.7	24
286	Molecular haplotyping of genomic DNA for multiple single-nucleotide polymorphisms located kilobases apart using long-range polymerase chain reaction and intramolecular ligation. Pharmacogenetics and Genomics, 2002, 12, 93-99.	5.7	71
287	Differing effects of methylenetetrahydrofolate reductase single nucleotide polymorphisms on methotrexate efficacy and toxicity in rheumatoid arthritis. Pharmacogenetics and Genomics, 2002, 12, 181-182.	5.7	22
288	Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia. Blood, 2002, 100, 43-47.	0.6	45

#	Article	IF	Citations
289	De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood, 2002, 100, 1240-1247.	0.6	87
290	Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia. Best Practice and Research in Clinical Haematology, 2002, 15, 741-756.	0.7	44
291	Molecular diagnostics as a predictive tool: genetics of drug efficacy and toxicity. Trends in Molecular Medicine, 2002, 8, 300-305.	3.5	54
292	Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell, 2002, 1, 133-143.	7.7	1,756
293	HPLC Determination of Thiopurine Nucleosides and Nucleotides in Vivo in Lymphoblasts following Mercaptopurine Therapy. Clinical Chemistry, 2002, 48, 61-68.	1.5	46
294	Childhood acute lymphoblastic leukemia. Reviews in Clinical and Experimental Hematology, 2002, 6, 161-180.	0.1	53
295	A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia. Cancer Chemotherapy and Pharmacology, 2002, 50, 419-428.	1.1	43
296	Comprehensive Assessment of Thiopurine S-Methyltransferase (TPMT) Alleles in Three Ethnic Populations. Journal of Pediatric Hematology/Oncology, 2002, 24, 335-336.	0.3	13
297	HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblasts following mercaptopurine therapy. Clinical Chemistry, 2002, 48, 61-8.	1.5	16
298	Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity. Clinical Cancer Research, 2002, 8, 2423-9.	3.2	38
299	PHARMACOGENOMICS: Unlocking the Human Genome for Better Drug Therapy. Annual Review of Pharmacology and Toxicology, 2001, 41, 101-121.	4.2	302
300	Pharmacodynamics of cancer chemotherapy: childhood ALL as a model. International Congress Series, 2001, 1220, 203-222.	0.2	0
301	PHARMACOGENOMICS: The Inherited Basis for Interindividual Differences in Drug Response. Annual Review of Genomics and Human Genetics, 2001, 2, 9-39.	2.5	365
302	Childhood acute lymphoblastic leukaemia â€“ current status and future perspectives. Lancet Oncology, The, 2001, 2, 597-607.	5.1	237
303	A Novel Protein Complex Distinct from Mismatch Repair Binds Thioguanylated DNA. Molecular Pharmacology, 2001, 59, 367-374.	1.0	51
304	Preponderance of Thiopurine S-Methyltransferase Deficiency and Heterozygosity Among Patients Intolerant to Mercaptopurine or Azathioprine. Journal of Clinical Oncology, 2001, 19, 2293-2301.	0.8	400
305	Resequencing the sulfotransferase SULT1 gene provides new insights, while illuminating challenges that lie ahead for pharmacogenomics. Pharmacogenetics and Genomics, 2001, 11, 745-746.	5.7	4
306	Unravelling the functional genomics of the human CYP2D6 gene locus. Pharmacogenetics and Genomics, 2001, 11, 553-554.	5.7	39

#	Article	IF	Citations
307	Second malignancy after treatment of childhood non-Hodgkin lymphoma. Cancer, 2001, 92, 1959-1966.	2.0	59
308	Deoxythioguanosine triphosphate impairs HIV replication: a new mechanism for an old drug. FASEB Journal, 2001, 15, 1902-1908.	0.2	13
309	Genetic Polymorphism of Thiopurine S-Methyltransferase: Molecular Mechanisms and Clinical Importance. Pharmacology, 2000, 61, 136-146.	0.9	152
310	Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia, 2000, 14, 567-572.	3.3	422
311	Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia, 2000, 14, 2286-2294.	3.3	187
312	Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood, 2000, 96, 3381-3384.	0.6	180
313	Late Effects of Treatment in Survivors of Childhood Acute Myeloid Leukemia. Journal of Clinical Oncology, 2000, 18, 3273-3279.	0.8	213
314	Hypersensitivity or Development of Antibodies to Asparaginase Does Not Impact Treatment Outcome of Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2000, 18, 1525-1532.	0.8	155
315	Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet, The, 2000, 356, 285-290.	6.3	181
316	Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood, 2000, 96, 3381-3384.	0.6	13
317	Acute Lymphoblastic Leukemia in Infants. Journal of Clinical Oncology, 1999, 17, 438-438.	0.8	27
318	Sex Differences in Prognosis for Children With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 1999, 17, 818-818.	0.8	128
319	Prognostic Importance of 6-Mercaptopurine Dose Intensity in Acute Lymphoblastic Leukemia. Blood, 1999, 93, 2817-2823.	0.6	348
320	Reduced Folate Carrier Expression in Acute Lymphoblastic Leukemia: A Mechanism for Ploidy but not Lineage Differences in Methotrexate Accumulation. Blood, 1999, 93, 1643-1650.	0.6	105
321	Mercaptopurine Therapy Intolerance and Heterozygosity at the Thiopurine S-Methyltransferase Gene Locus. Journal of the National Cancer Institute, 1999, 91, 2001-2008.	3.0	680
322	Polymorphism of the thiopurine S-methyltransferase gene in African- Americans. Human Molecular Genetics, 1999, 8, 371-376.	1.4	239
323	An interview with a distinguished pharmaceutical scientist. William E. Evans. Pharmaceutical Research, 1999, 16, 785-789.	1.7	2
324	Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. , 1999, 16, 342-349.		113

#	Article	IF	Citations
325	Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics. Science, 1999, 286, 487-491.	6.0	2,291
326	High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet, The, 1999, 354, 34-39.	6.3	390
327	Synthesis of Modified Thiopurine Nucleosides for Structural Characterization of Human Thiopurine S-Methyltransferase. Nucleosides & Nucleotides, 1999, 18, 1747-1748.	0.5	3
328	Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells. Pharmacogenetics and Genomics, 1999, 9, 641???650.	5.7	31
329	Genetic Abnormalities and Drug Resistance in Acute Lymphoblastic Leukemia. Advances in Experimental Medicine and Biology, 1999, 457, 383-389.	0.8	8
330	Defining the Optimal Dosage of Methotrexate for Childhood Acute Lymphoblastic Leukemia. Advances in Experimental Medicine and Biology, 1999, 457, 537-541.	0.8	5
331	Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells. Pharmacogenetics and Genomics, 1999, 9, 641-650.	0.7	88
332	Reduced Folate Carrier Expression in Acute Lymphoblastic Leukemia: A Mechanism for Ploidy but not Lineage Differences in Methotrexate Accumulation. Blood, 1999, 93, 1643-1650.	0.6	3
333	Prognostic Importance of 6-Mercaptopurine Dose Intensity in Acute Lymphoblastic Leukemia. Blood, 1999, 93, 2817-2823.	0.6	33
334	Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans*. Clinical Pharmacology and Therapeutics, 1998, 64, 46-51.	2.3	76
335	Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia, 1998, 12, 346-352.	3.3	179
336	Functional characterization of the human thiopurine S-methyltransferase (TPMT) gene promoter. FEBS Journal, 1998, 256, 510-517.	0.2	31
337	Molecular cloning and functional characterization of the cDNA encoding the murine thiopurineS-methyltransferase (TPMT). FEBS Letters, 1998, 424, 143-145.	1.3	10
338	Pharmacogenetics of Cancer Therapy: Getting Personal. American Journal of Human Genetics, 1998, 63, 11-16.	2.6	134
339	Conventional Compared with Individualized Chemotherapy for Childhood Acute Lymphoblastic Leukemia. New England Journal of Medicine, 1998, 338, 499-505.	13.9	438
340	Acute Lymphoblastic Leukemia. New England Journal of Medicine, 1998, 339, 605-615.	13.9	809
341	In Vivo., Toxicity and Pharmacokinetic Features of B43(Anti-CD19)-Genistein Immunoconjugate. Leukemia and Lymphoma, 1998, 30, 389-394.	0.6	13
342	Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia.. Journal of Clinical Oncology, 1998, 16, 3768-3773.	0.8	89

#	Article	IF	Citations
343	Early Intensification of Intrathecal Chemotherapy Virtually Eliminates Central Nervous System Relapse in Children With Acute Lymphoblastic Leukemia. Blood, 1998, 92, 411-415.	0.6	183
344	Pharmacodynamic Monitoring of Cancer Chemotherapy: Childhood Acute Lymphoblastic Leukemia as a Model. Therapeutic Drug Monitoring, 1998, 20, 453-458.	1.0	4
345	Early Intensification of Intrathecal Chemotherapy Virtually Eliminates Central Nervous System Relapse in Children With Acute Lymphoblastic Leukemia. Blood, 1998, 92, 411-415.	0.6	6
346	Human Granulocyte Colony-Stimulating Factor after Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia. New England Journal of Medicine, 1997, 336, 1781-1787.	13.9	158
347	Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): Mechanisms for the genetic polymorphism of TPMT activity. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 6444-6449.	3.3	262
348	Molecular Diagnosis of Thiopurine S-Methyltransferase Deficiency: Genetic Basis for Azathioprine and Mercaptopurine Intolerance. Annals of Internal Medicine, 1997, 126, 608.	2.0	679
349	Differences in Folylpolyglutamate Synthetase and Dihydrofolate Reductase Expression in Human B-Lineage versus T-Lineage Leukemic Lymphoblasts: Mechanisms for Lineage Differences in Methotrexate Polyglutamylation and Cytotoxicity. Molecular Pharmacology, 1997, 52, 155-163.	1.0	95
350	TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance.. Journal of Clinical Oncology, 1997, 15, 1150-1157.	0.8	198
351	Higher Frequency of Glutathione S-Transferase Deletions in Black Children With Acute Lymphoblastic Leukemia. Blood, 1997, 89, 1701-1707.	0.6	283
352	Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia, 1997, 11, 1813-1816.	3.3	154
353	Does pharmacokinetic variability influence the efficacy of high-dose methotrexate for the treatment of children with acute lymphoblastic leukemia: What can we learn from small studies?. Leukemia Research, 1997, 21, 435-437.	0.4	16
354	Promoter and intronic sequences of the human thiopurine S-methyltransferase (TPMT) gene isolated from a human PAC1 genomic library. Pharmaceutical Research, 1997, 14, 1672-1678.	1.7	47
355	Higher Frequency of Glutathione S-Transferase Deletions in Black Children With Acute Lymphoblastic Leukemia. Blood, 1997, 89, 1701-1707.	0.6	8
356	Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia.. Journal of Clinical Oncology, 1996, 14, 1504-1511.	0.8	67
357	Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia.. Journal of Clinical Oncology, 1996, 14, 399-404.	0.8	59
358	Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia.. Journal of Clinical Oncology, 1996, 14, 2370-2376.	0.8	125
359	Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics and Genomics, 1996, 6, 279-290.	5.7	253
360	Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: Pharmacokinetic characteristics. , 1996, 26, 85-89.		34

#	Article	IF	Citations
361	Hepatic drug clearance in patients with mild cystic fibrosis*. Clinical Pharmacology and Therapeutics, 1996, 59, 529-540.	2.3	21
362	Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.. Journal of Clinical Investigation, 1996, 97, 73-80.	3.9	177
363	Targeted Drug Therapy in Childhood Acute Lymphoblastic Leukemia. Hamatologie Und Bluttransfusion, 1996, , 62-66.	0.0	0
364	A Longitudinal Study of Granulocyte Colony-Stimulating Factor Levels and Neutrophil Counts in Newborn Infants. Journal of Pediatric Hematology/Oncology, 1995, 17, 176-179.	0.3	17
365	Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults. Pharmacogenetics and Genomics, 1995, 5, 281-286.	5.7	74
366	A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 949-953.	3.3	316
367	Pharmacokinetics of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Children after Intravenous and Subcutaneous Administration. Journal of Pharmaceutical Sciences, 1995, 84, 824-828.	1.6	29
368	Ligation of CD38 suppresses human B lymphopoiesis.. Journal of Experimental Medicine, 1995, 181, 1101-1110.	4.2	140
369	Favorable Pharmacodynamic Features and Superior Anti-Leukemic Activity of B43 (Anti-CD 19) Immunotoxins Containing Two Pokeweed Antiviral Protein Molecules Covalently Linked to each Monoclonal Antibody Molecule. Leukemia and Lymphoma, 1995, 18, 93-102.	0.6	10
370	Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science, 1995, 267, 886-891.	6.0	276
371	Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia.. Journal of Clinical Investigation, 1994, 94, 1996-2001.	3.9	180
372	Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Human Molecular Genetics, 1994, 3, 923-926.	1.4	101
373	High-dose dextromethorphan in amyotrophic lateral sclerosis: Phase I safety and pharmacokinetic studies. Annals of Neurology, 1994, 36, 920-924.	2.8	63
374	Mercaptopurine vs thioguanine for the treatment of acute lymphoblastic leukemia. Leukemia Research, 1994, 18, 811-814.	0.4	22
375	Thiopurine methyltransferase activity in American white subjects and black subjects. Clinical Pharmacology and Therapeutics, 1994, 55, 15-20.	2.3	242
376	Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. Journal of Pediatrics, 1994, 125, 642-649.	0.9	119
377	Patient characteristics associated with high-risk methotrexate concentrations and toxicity.. Journal of Clinical Oncology, 1994, 12, 1667-1672.	0.8	191
378	Disposition of recombinant human granulocyte colony-stimulating factor in children with severe chronic neutropenia. Journal of Pediatrics, 1993, 123, 471-479.	0.9	59

#	Article	IF	Citations
379	Alternative Approaches for Phase I Studies of Anticancer Drugs. Therapeutic Drug Monitoring, 1993, 15, 492-497.	1.0	11
380	Escalating teniposide systemic exposure to increase dose intensity for pediatric cancer patients.. Journal of Clinical Oncology, 1993, 11, 287-293.	0.8	26
381	Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans.. Journal of Clinical Investigation, 1993, 91, 2150-2154.	3.9	92
382	Increased teniposide clearance with concomitant anticonvulsant therapy.. Journal of Clinical Oncology, 1992, 10, 311-315.	0.8	79
383	Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2* activities. Clinical Pharmacology and Therapeutics, 1992, 52, 643-658.	2.3	295
384	Factors Affecting In Vitro Protein Binding of Etoposide in Humans. Journal of Pharmaceutical Sciences, 1992, 81, 259-264.	1.6	16
385	Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. Journal of Pediatrics, 1991, 119, 985-989.	0.9	402
386	Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet, The, 1991, 337, 61-66.	6.3	351
387	Lipoprotein Analysis in the Evaluation of Chest Pain in the Emergency Department. Mayo Clinic Proceedings, 1991, 66, 885-891.	1.4	6
388	Risk of adverse events in children completing treatment for acute lymphoblastic leukemia: St. Jude Total Therapy studies VIII, IX, and X.. Journal of Clinical Oncology, 1991, 9, 1341-1347.	0.8	35
389	Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy.. Journal of Clinical Oncology, 1991, 9, 1022-1028.	0.8	81
390	Age-related differences in hepatic drug clearance in children: Studies with lorazepam and antipyrine. Clinical Pharmacology and Therapeutics, 1991, 50, 132-140.	2.3	44
391	Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clinical Pharmacology and Therapeutics, 1991, 50, 308-313.	2.3	105
392	Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clinical Pharmacology and Therapeutics, 1991, 50, 385-393.	2.3	88
393	Concept of maximum tolerated systemic exposure and its application to phase I-II studies of anticancer drugs. Medical and Pediatric Oncology, 1991, 19, 153-159.	1.0	36
394	Pharmacokinetics of continuous-infusion amsacrine and teniposide for the treatment of relapsed childhood acute nonlymphocytic leukemia. Cancer Chemotherapy and Pharmacology, 1991, 27, 397-400.	1.1	7
395	Acute Myeloid Leukemia in Children Treated with Epipodophyllotoxins for Acute Lymphoblastic Leukemia. New England Journal of Medicine, 1991, 325, 1682-1687.	13.9	697
396	Aspirin alters methotrexate disposition in rheumatoid arthritis patients. Arthritis and Rheumatism, 1991, 34, 1514-1520.	6.7	71

#	Article	IF	Citations
397	Clinical pharmacology of anticancer drugs in children. Current Opinion in Pediatrics, 1990, 2, 254-260.	1.0	0
398	Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis. Clinical Pharmacology and Therapeutics, 1990, 47, 540-546.	2.3	56
399	Adjuvant chemotherapy for osteosarcoma of the extremity long-term results of two consecutive prospective protocol studies. Cancer, 1990, 65, 439-445.	2.0	48
400	Changes in the clearance of total and unbound etoposide in patients with liver dysfunction.. Journal of Clinical Oncology, 1990, 8, 1874-1879.	0.8	76
401	Enhanced hepatic drug clearance in patients with cystic fibrosis. Journal of Pediatrics, 1990, 117, 972-979.	0.9	45
402	Advances in pediatric pharmacokinetics and therapeutics. Journal of Pediatrics, 1990, 117, 996-1001.	0.9	2
403	Anticancer Therapy as a Pediatric Pharmacodynamic Paradigm. Developmental Pharmacology and Therapeutics, 1989, 13, 85-95.	0.2	7
404	Synthesis of potential antifilarial agents 2 . methyl 2â€substituted purine 8â€carbamates and related compounds. Journal of Heterocyclic Chemistry, 1989, 26, 1053-1059.	1.4	7
405	Hepatic Drug Clearance in Children: Studies with Indocyanine Green as a Model Substrate. Journal of Pharmaceutical Sciences, 1989, 78, 452-456.	1.6	35
406	Improved high-performance liquid chromatographic method using loop-column extraction for analysis of idarubicin and idarubicinol in plasma. Biomedical Applications, 1989, 491, 501-506.	1.7	7
407	Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. Clinical Pharmacology and Therapeutics, 1989, 45, 568-573.	2.3	95
408	Altered protein binding of etoposide in patients with cancer. Clinical Pharmacology and Therapeutics, 1989, 45, 49-55.	2.3	81
409	Lorazepam pharmacodynamics and pharmacokinetics in children. Journal of Pediatrics, 1989, 114, 641-646.	0.9	37
410	Clinical Pharmacokinetics-Pharmacodynamicsof Anticancer Drugs. Clinical Pharmacokinetics, 1989, 16, 327-336.	1.6	112
411	Clinical Pharmacology of Cancer Chemotherapy in Children. Pediatric Clinics of North America, 1989, 36, 1199-1230.	0.9	31
412	Removal of methotrexate, leucovorin, and their metabolites by combined hemodialysis and hemoperfusion. Cancer, 1988, 62, 884-888.	2.0	77
413	High-dose methotrexate improves clinical outcome in children with acute lymphoblastic leukemia: St. Jude total therapy study X. Medical and Pediatric Oncology, 1988, 16, 297-303.	1.0	61
414	Clinical pharmacodynamics of anticancer drugs: a basis for extending the concept of dose-intensity. Blut, 1988, 56, 241-248.	1.2	41

#	Article	IF	Citations
415	Drug Concentration Monitoring. Progress in Clinical Biochemistry and Medicine, 1988, , 1-16.	0.5	1
416	Academic Research Fellowships in Clinical Pharmacy. Drug Intelligence & Clinical Pharmacy, 1987, 21, 106-109.	0.4	0
417	Methotrexate bioavailability after oral and intramuscular administration in children. Journal of Pediatrics, 1987, 110, 788-792.	0.9	69
418	Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. Journal of Pediatrics, 1987, 111, 606-612.	0.9	95
419	Pharmacokinetics of Anticancer Drugs in Children. Clinical Pharmacokinetics, 1987, 12, 168-213.	1.6	62
420	Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial.. Journal of Clinical Oncology, 1987, 5, 1007-1014.	0.8	117
421	Simultaneous administration of multiple model substrates to assess hepatic drug clearance. Clinical Pharmacology and Therapeutics, 1987, 41, 645-650.	2.3	39
422	Hepatic drug clearance in children with leukemia: Changes in clearance of model substrates during remission-induction therapy. Clinical Pharmacology and Therapeutics, 1987, 41, 651-660.	2.3	36
423	Clinical pharmacology of anticancer drugs in children: differences and similarities between children and adults. , 1987, , 29-71.		0
424	Clinical Pharmacodynamics of High-Dose Methotrexate in Acute Lymphocytic Leukemia. New England Journal of Medicine, 1986, 314, 471-477.	13.9	369
425	Etoposide pharmacokinetics in patients with normal and abnormal organ function.. Journal of Clinical Oncology, 1986, 4, 1690-1695.	0.8	91
426	Simultaneous analysis of antipyrine and lorazepam by high-performance liquid chromatography. Biomedical Applications, 1986, 382, 199-205.	1.7	16
427	Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance. Clinical Pharmacology and Therapeutics, 1986, 39, 592-597.	2.3	14
428	Loop-Column Extraction and Liquid Chromatographic Analysis of Doxorubicin and Three Metabolites in Plasma. Therapeutic Drug Monitoring, 1985, 7, 455-460.	1.0	20
429	High-performance liquid chromatographic assay of mitomycin in biological fluids. Biomedical Applications, 1985, 345, 197-202.	1.7	12
430	Unexpectedly severe toxicity from intensive early treatment of childhood lymphoblastic leukemia.. Journal of Clinical Oncology, 1985, 3, 201-206.	0.8	38
431	The effect of prior cisplatin therapy on the pharmacokinetics of high-dose methotrexate.. Journal of Clinical Oncology, 1984, 2, 655-661.	0.8	47
432	High-Performance Liquid Chromatographic Analysis of the Semisynthetic Epipodophyllotoxins Teniposide and Etoposide Using Electrochemical Detection. Journal of Pharmaceutical Sciences, 1984, 73, 164-168.	1.6	58

#	Article	IF	Citations
433	Reaction III. Drug Intelligence & Clinical Pharmacy, 1984, 18, 331-332.	0.4	1
434	Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion. Clinical Pharmacology and Therapeutics, 1983, 33, 301-307.	2.3	78
435	Bleomycin disposition in children with cancer. Clinical Pharmacology and Therapeutics, 1983, 33, 668-673.	2.3	17
436	High-performance liquid chromatographic assay for cytosine arabinoside, uracil arabinoside and some related nucleosides. Biomedical Applications, 1983, 274, 87-93.	1.7	21
437	Pharmacokinetics of Anticancer Drugs in Children. Drug Metabolism Reviews, 1983, 14, 847-886.	1.5	22
438	A Simple Preparation of the Methotrexate Metabolites 7-Hydroxymethotrexate and 4-Deoxy-4-amino-N10-methylpteroic Acid. Therapeutic Drug Monitoring, 1983, 5, 363-366.	1.0	15
439	Clinical Pharmacology of Bleomycin and Cisplatin. Drug Intelligence & Clinical Pharmacy, 1982, 16, 448-458.	0.4	13
440	Disposition of Intermediate-Dose Methotrexate in Children with Acute Lymphocytic Leukemia. Drug Intelligence & Clinical Pharmacy, 1982, 16, 839-842.	0.4	24
441	A Randomized-Blinded Evaluation of Analytical Error Associated with the Enzyme Immunoassay (EMITÂ®) of Gentamicin. Therapeutic Drug Monitoring, 1982, 4, 409-412.	1.0	0
442	ACCP Forms Specialty Committee. American Journal of Health-System Pharmacy, 1982, 39, 44-46.	0.5	0
443	Anaphylactoid reactions to escherichia coli and erwinia asparaginase in children with leukemia and lymphoma. Cancer, 1982, 49, 1378-1383.	2.0	99
444	High-performance liquid chromatographic assay of methotrexate, 7-hydroxymethotrexate, 4-deoxy-4-amino-N10-methylpteroic acid and sulfamethoxazole in serum, urine and cerebrospinal fluid. Biomedical Applications, 1982, 231, 103-110.	1.7	21
445	Quantitation of daunorubicin and its metabolites by high-performance liquid chromatography with electrochemical detection. Biomedical Applications, 1982, 232, 377-383.	1.7	26
446	Pharmacokinetics of teniposide (VM26) and etoposide (VP16-213) in children with cancer. Cancer Chemotherapy and Pharmacology, 1982, 7, 147-50.	1.1	100
447	Reappraisal of Guidelines for Pharmacokinetic Monitoring of Aminoglycosides. Pharmacotherapy, 1981, 1, 55-75.	1.2	25
448	Clinical evaluation of sequentially scheduled cisplatin and vm26 in neuroblastoma: Response and toxicity. Cancer, 1981, 48, 1715-1718.	2.0	107
449	Pharmacokinetics of Sustained Serum Methotrexate Concentrations Secondary to Gastrointestinal Obstruction. Journal of Pharmaceutical Sciences, 1981, 70, 1194-1198.	1.6	16
450	Clinical pharmacology of bleomycin and cisplatin. Head & Neck, 1981, 4, 98-110.	0.3	33

#	Article	IF	Citations
451	Effect of hepatic irradiation on the toxicity and pharmacokinetics of adriamycin in children. International Journal of Radiation Oncology Biology Physics, 1981, 7, 953-956.	0.4	13
452	Cisplatin disposition in children and adolescents with cancer. Cancer Chemotherapy and Pharmacology, 1981, 6, 95-9.	1.1	36
453	The Clinical Pharmacist and Research. Journal of Clinical Pharmacology, 1981, 21, 241-244.	1.0	8
454	Accuracy of Using Pre- and Postdose Gentamicin Serum Concentrations to Estimate Pharmacokinetic Parameters and Adjust Doses in Children and Adolescents. Therapeutic Drug Monitoring, 1981, 3, 57-62.	1.0	14
455	A Model for Dosing Gentamicin in Children and Adolescents that Adjusts for Tissue Accumulation with Continuous Dosing1. Clinical Pharmacokinetics, 1980, 5, 295-306.	1.6	40
456	PHASE II EVALUATION OF CISPLATIN IN CHILDREN WITH NEUROBLASTOMA AND OTHER MALIGNANT SOLID TUMORS. , 1980, , 477-484.		3
457	Pharmacokinetic monitoring of high-dose methotrexate. Cancer Chemotherapy and Pharmacology, 1979, 3, 161-6.	1.1	102
458	Gentamicin dosage in children: A randomized prospective comparison of body weight and body surface area as dose determinants. Journal of Pediatrics, 1979, 94, 139-143.	0.9	16
459	Use of gentamicin serum levels to individualize therapy in children. Journal of Pediatrics, 1978, 93, 133-137.	0.9	28
460	Treatment of the Totally Occluded Abdominal Aorta. Vascular Surgery, 1978, 12, 287-293.	0.3	0
461	Effect of pleural effusion on highâ€dose methotrexate kinetics. Clinical Pharmacology and Therapeutics, 1978, 23, 68-72.	2.3	85
462	Comparison of Antibiotic Serum Concentrations After Intramuscular Oxacillin and Oral Cloxacillin in Children. American Journal of Health-System Pharmacy, 1978, 35, 1380-1382.	0.5	0
463	Lead Poisoning from Ingestion of Chinese Herbal Medicine. Clinical Toxicology, 1977, 10, 273-281.	0.5	42
464	Microbiological Hazards of Infusion Therapy. American Journal of Health-System Pharmacy, 1977, 34, 775-775.	0.5	0
465	Unit dose radiopharmaceutical service as a component of total pharmacy practice. American Journal of Health-System Pharmacy, 1976, 33, 61-63.	0.5	0
466	Double-blind evaluation of 5-Î¼m final filtration to reduce postinfusion phlebitis. American Journal of Health-System Pharmacy, 1976, 33, 1160-1163.	0.5	4
467	Phenobarbital-Induced Hepatic Dysfunction. Drug Intelligence & Clinical Pharmacy, 1976, 10, 439-443.	0.4	14
468	Acute Renal Failure in a Multisystem Allergic Reaction to Sulfamethoxazole. Drug Intelligence & Clinical Pharmacy, 1975, 9, 660-662.	0.4	1

#	Article	IF	Citations
469	Chloral Hydrateâ€"Warfarin Interaction. American Journal of Health-System Pharmacy, 1975, 32, 241-243.	0.5	0
470	Pharmacokinetic, pharmacodynamic, and pharmacogenetic considerations. , 0, , 309-331.		0
471	Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. SSRN Electronic Journal, 0, , .	0.4	0